Expand all sections

Afatinib

Giotrif

Extended indication Head and neck (or upper airways tract) cancers, locally advanced (recurrent/metastatic) squamous cel
Therapeutic value No judgement
Registration phase Clinical trials

Product

Active substance Afatinib
Domain Oncology and Hematology
Reason of inclusion Indication extension
Main indication Head and neck cancer
Extended indication Head and neck (or upper airways tract) cancers, locally advanced (recurrent/metastatic) squamous cell, 2nd line after platinum therapy
Proprietary name Giotrif
Manufacturer Boehringer Ingelheim
Mechanism of action Tyrosine kinase inhibitor
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Intermural (MSZ)
Additional remarks antineoplastische stoffen, proteïnekinaseremmers

Registration

Registration route Centralised (EMA)
Expected Registration 2021
Orphan drug No
Registration phase Clinical trials
Additional remarks Al op de markt voor EGFR+ NSCLC, 1L en plaveiselcel NSCLC, 2L.

Therapeutic value

Current treatment options Methotrexate. Andere immunotherapiën en PD1/PDL1-remmers.
Therapeutic value No judgement
Frequency of administration 1 times a day
Dosage per administration 40 mg

Expected patient volume per year

References NKR 2015
Additional remarks Hoofd-hals tumoren, stadium 3 en 4, respectivelijk 427 en 1.189 (in totaal 1.616). Gezien het gaat om een 2L behandeling en gezien de huidige behandelopties / concurrentie zal het realistisch patiëntvolume lager liggen.

Expected cost per patient per year

Cost 25,000.00
References G-standaard; Fabrikant
Additional remarks De prijs van het middel dat nu al op de markt is voor NSCLC is €2113.57 per maand.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension No
References clinicaltrials.gov

Other information

There is currently no futher information available.